ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
January 15, 2019Astellas Pharma Canada, Inc., today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for the treatment of patients with prostate cancer, following a Priority Review by Health Canada's Therapeuti
Pharma Sources Insight January 2025
